Stock Analiz

Monte Rosa Therapeutics, Inc. (GLUE) stock forecast and price target

Price $9.37 · data as of November 13, 2026

12-month price target

Average target$25.38
Upside / downside+170.8%
Analysts8
ConsensusStrong buy
Low $15.00Average $25.38High $37.00

Gold marker: average target · white marker: today’s price ($9.37)

Analyst ratings

Strong buy 2Buy 8Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-1.02−122.4%$102M
Next fiscal year
ends December 31, 2027
$-1.78−73.6%$62M
Next quarter
ends December 31, 2026
$-0.20+63.1%$32M
Quarter after
ends March 31, 2027
$-0.46−2.7%$4M

Consensus of the analysts covering Monte Rosa Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 1 lowered.

Frequently asked questions

What is the Monte Rosa Therapeutics stock price target?

The average 12-month target from 8 analysts is $25.38, 170.8% above the current price of $9.37 Targets range from $15.00 to $37.00.

Is Monte Rosa Therapeutics a buy according to analysts?

The consensus rating is “Strong buy” (2 strong buy, 8 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is Monte Rosa Therapeutics expected to earn?

Analysts expect EPS of $-1.02 for the fiscal year ending December 31, 2026 and $-1.78 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.